Technical Analysis

Aurobindo Pharma (₹604.1): Buy

Yoganand D BL Research Bureau | Updated on July 10, 2019 Published on July 10, 2019

The stock of Aurobindo Pharma almost gained 3 per cent with good volume on Tuesday, rebounding from a key support at around ₹582. Investors with a short-term view can buy the stock at current levels. Since encountering a key resistance at ₹838 in late April 2019, the stock has been in a medium-term downtrend. While trending down, the stock had breached a key support at ₹750 and ₹700 and continued to trend down. But the stock found support in the band between ₹575 and ₹585 in late June.

After testing this support, the stock reversed higher recently. The daily relative strength index as well as price rate of change indicators are displaying positive divergence implying possibility of a trend reversal. Also, the daily RSI has entered the neutral region from the bearish zone and the weekly RSI is likely to recover from the oversold territory. The daily price rate of change indicator has entered the positive terrain indicating buying interest.

Taking a contrarian stance, the short-term outlook is bullish for the stock. It can continue to trend upwards and reach the price targets of ₹628 and ₹640 in the ensuing trading session. Traders can buy the stock with a stop-loss at ₹592.

(Note: The recommendations are based on technical analysis. There is a risk of loss in trading.)

Published on July 10, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.